Navigation Links
Daiichi Sankyo Settled Patent Litigation for Evoxac®
Date:8/4/2010

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Daiichi Sankyo, Inc. and its parent company, Daiichi Sankyo Co., Ltd, (collectively, "Daiichi Sankyo") have reached an agreement with Apotex Inc. and Apotex Corp. (collectively, "Apotex") to settle their patent litigation involving Apotex's challenge to Daiichi Sankyo's U.S. Patent Number 5,340,821 (hereinafter referred to as "the '821 patent") covering Evoxac® (cevimeline HCl).  Under the agreement, Apotex has received a license to the '821 patent that will permit Apotex to commercially launch its generic cevimeline HCl product in the fourth quarter of 2012.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please v
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
2. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
3. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
4. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
5. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
8. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 2011 PRA, a leading Clinical Research Organization, announces ... Wanger,s book, Pulmonary Function Testing: A Practical Approach ... Learning in Sudbury, MA. Mr. Wanger, ... wrote the textbook for both respiratory care students and ...
... 2011 Cardium Therapeutics (NYSE Amex: CXM ... seeking clearance from the U.S. Food and Drug Administration ... care management medical device comprising 2.6% formulated bovine Type ...  In addition to diabetic foot ulcers, dermal wounds for ...
Cached Medicine Technology:PRA Expert's Pulmonary Function Textbook Reissued 2Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans 2Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans 3Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans 4Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans 5
(Date:4/17/2014)... April 2014) Population Council scientists and their partners have ... and can prevent the transmission of multiple sexually transmitted ... animals: HIV, herpes simplex virus 2 (HSV-2), and human ... data that the gel is effective against multiple strains ... the vagina against all three viruses of at least ...
(Date:4/17/2014)... less than 40 years away from a food shortage ... according to a top scientist at the U.S. Agency ... history, food production will be limited on a global ... said Dr. Fred Davies, senior science advisor for the ... as politically destabilizing by 2050 as energy issues are ...
(Date:4/17/2014)... work has transformed cancer care in Northern Ireland, has ... of Cancer Sciences., The Academy, which was launched in ... oncologists and cancer researchers which aims to reduce the ... Professor Johnston, whose leadership has seen cancer survival rates ... UK league table to near the top, has been ...
(Date:4/16/2014)... PHOENIX, Ariz. April 15, 2014 The Translational ... philanthropists at their annual Founders Dinner for their support ... The event took place March 28 in Scottsdale. , ... Catherine Ivy Foundation, received TGen,s John S. McCain Leadership ...
(Date:4/16/2014)... fertility treatments are the leading cause of increases in ... of premature birth, these results are not inevitable, concludes ... . The article identifies six changes in policy and ... and prematurity, including expanding insurance coverage for in vitro ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
... , ... solution will support compliance and risk management centered on internal and financial controls. ... (PRWEB) May 21, ... solutions announced today that TPG Capital, a leading private investment firm, has selected the ...
... pressure monitoring (HBPM) program supported by the American Heart ... for patients with uncontrolled hypertension, according to a study. ... 18 to 85 years, and with Internet access were ... HBPM group. All patients had their blood pressure measured ...
... 2010 New and universally applicable definitions of malnutrition are ... These are the result of a major international collaboration that ... ASPEN. The importance of the work is emphasised by ... publication in Clinical Nutrition and the ASPEN journal ...
... But study finds that many don,t get counseling on when it,s ... People who don,t have a frank talk about sex with their ... to resume sexual activity, new research finds. , The study of ... the men were 30 percent more likely and women 40 percent ...
... ... leading information technology research and advisory company, recently released a case study that describes ... costs and months of internal development time by outsourcing its international card payment operations ... ...
... ... City, Utah and Clemson University, Clemson, South Carolina has signed a Memorandum of ... with Clemson University will develop existing and future products in the field of ... energy currently required by RO or Evaboration type processes. , ...
Cached Medicine News:Health News:TPG Capital Selects MetricStream GRC Platform to Boost its Internal Controls and Compliance 2Health News:Talk With Doctor Helps Heart Attack Patients Resume Sex 2Health News:Talk With Doctor Helps Heart Attack Patients Resume Sex 3Health News:Insightful Case Study Details How Electronic Payment Exchange Saved a Global Firm More Than $3 Million in PCI-Related Costs 2Health News:Water Enabled Technologies of Utah Signs MOU with Clemson University, South Carolina, for Water Desalination 2
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
The First Aid for the Surgery Clerkship is designed to prepare for the surgery clerkship examination and provides clinical diagnosis and treatment of many of the problems seen by surgeons....
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician....
... enable all those involved with healthcare decisions ... very latest evidence in their field of ... each year as the volume of evidence ... delivering the best single source available for ...
Medicine Products: